Results for tag: "Orexin Receptor Type 2"

The Orexin Receptor Type 2 (OX2R) market is a subset of the Central Nervous System (CNS) Drugs market. OX2R is a G-protein coupled receptor that is involved in the regulation of sleep and wakefulness. It is also involved in the regulation of appetite, reward, and stress. OX2R agonists are being developed as potential treatments for insomnia, narcolepsy, and other sleep disorders. OX2R antagonists are being developed as potential treatments for obesity, addiction, and other CNS disorders. Several companies are involved in the OX2R market, including Merck, Pfizer, AstraZeneca, and GlaxoSmithKline. Other companies, such as Novartis, Sanofi, and Takeda, are also researching OX2R-targeted therapies. Additionally, several biotechnology companies, such as Arena Pharmaceuticals, Orexigen Therapeutics, and Vanda Pharmaceuticals, are developing OX2R-targeted therapies. Show Less Read more